Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

Fig. 3

Summary results of efficacy outcomes for the first-line treatment. (A Life-year results within 10 years for first-line therapies’ PFS. B Cox-PH model result for first-line therapies’ OS). Abbreviations: Abema, Abemaciclib; ANA, Anastrozole; BEV, Bevacizumab; EXE, Exemestane; FUL, Fulvestrant; LET, Letrozole; Palbo, Palbociclib; Ribo, Ribociclib. Note: The direction of the reported relative effects in each cell is defined as treatment on the right vs. treatment on the left. Values < 1 favor the intervention on the right. Values in parenthesis are 95% credible intervals (95% CIs). Bold cells correspond to statistically significant relative effects for the respective treatment categories

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us